Animal Cell, Per Se, Expressing Immunoglobulin, Antibody, Or Fragment Thereof Patents (Class 435/326)
  • Patent number: 10207011
    Abstract: Described herein are methods, systems, and devices for identifying agents and genetic pathways that modulate the effects of traumatic brain injury (TBI) in invertebrate model systems having a brain, e.g., Drosophila or C. elegans.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: February 19, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Barry S. Ganetzky, David A. Wassarman
  • Patent number: 10196665
    Abstract: This invention relates to a novel cell culture medium and methods to enhance recombinant antibody purity using the cell culture medium disclosed herein. The novel cell culture medium is a self-made feeding medium, which comprises from about 90 nM to about 500 mM cysteine, from about 50 mM to about 500 mM tyrosine, and from about 50 mM to about 300 tryptophan. This invention also relates to a method of growing cell culture using the cell culture medium disclosed herein By controlling the concentration of cysteine in the self-made feed medium as well as the amount and time of adding this feed medium into the cell culture, the purity of antibodies is significantly improved while glycosylation profile and antibody expression level are consistently maintained to guarantee the efficacy of antibodies.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 5, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiwen Cheng, Chengwei Yan, Bin Yang, Wen-Chen Suen, Yuancan Weng, Chongfei Deng
  • Patent number: 10183994
    Abstract: The invention relates to anti-TNF? antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF? antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 22, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ralf Guenther, Stefan Becker, Laura Rhiel, Bjoern Hock, Christian Schroeter
  • Patent number: 10172889
    Abstract: Novel adult liver progenitor cells (called H2Stem Cells) have been have been characterized on the basis of a series of biological activities and markers. Methods for producing H2Stem Cells allow providing such cells in the form of adherent cells and three-dimensional cell clusters in suspension that can be differentiated into cells having strong liver-specific activities and/or that can be used for treating liver diseases or for evaluating the efficacy, the metabolism, and/or toxicity of a compound.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 8, 2019
    Assignee: Promethera Biosciences S.A./N.V.
    Inventors: Etienne Sokal, Sarah Snykers, Tuba Baran, Kris Gellynck
  • Patent number: 10047147
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 14, 2018
    Assignee: The United States of American, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose
  • Patent number: 10034902
    Abstract: A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 31, 2018
    Assignees: EXOSTEM BIOTEC LTD., HENRY FORD HEALTH SYSTEM
    Inventors: Chaya Brodie, Shimon Slavin
  • Patent number: 9797903
    Abstract: Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 24, 2017
    Assignee: WINTHROP-UNIVERSITY HOSPITAL
    Inventor: Louis Ragolia
  • Patent number: 9764038
    Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 19, 2017
    Assignees: INNATE PHARMA, PAUL SCHERRER INSTITUT
    Inventors: Patrick Dennler, Delphine Bregeon, Laurent Gauthier, François Romagné, Christian Belmant, Eliane Fischer, Roger Schibli
  • Patent number: 9751944
    Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 5, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
  • Patent number: 9738708
    Abstract: Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of BGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AND), diabetic retinopathy and cancer using the fusion proteins described herein.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 22, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jan Kitajewski, Carrie Shawber, Thaned Kangsamaksin
  • Patent number: 9683051
    Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: June 20, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Masazumi Kamohara, Shigenori Yagi, Yoshinori Ishii, Hiromi Nara
  • Patent number: 9675676
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 13, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 9645138
    Abstract: The invention relates to a method for evaluating whether a molecule of interest binds or is incorporated in at least one target tissue, comprising visualizing and comparing the distribution of the molecule of interest and of at least one control compound within the target tissue or on the target tissue surface of at least one animal that has previously received the molecule of interest and/or the control compound. Advantageously, the distribution of the molecule of interest is visualized and compared with the distribution of positive and negative compounds using mass spectrometry imaging on the surface of the target tissue.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: May 9, 2017
    Assignee: IMABIOTECH
    Inventors: Grégory Hamm, Jonathan Stauber
  • Patent number: 9629903
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 25, 2017
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 9364514
    Abstract: A chimeric peptide construct having a cell penetrating peptide linked to a pro-apoptotic peptide. The construct can be used for treating a tumor in combination with an anti-tumor agent. Also disclosed is a method for treating a tumor with the chimeric peptide construct and a chemotherapeutic agent.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: June 14, 2016
    Assignees: Institute Curie, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Angelita Rebollo Garcia, Fariba Nemati, Didier Decaudin
  • Patent number: 9328333
    Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: May 3, 2016
    Assignee: EPITOMICS, Inc.
    Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
  • Patent number: 9198981
    Abstract: This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: December 1, 2015
    Assignee: The University of Kentucky
    Inventors: Balamurali Krishna Ambati, Jayakrishna Ambati, Nirbhai Singh
  • Publication number: 20150147343
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 28, 2015
    Applicant: University of Zurich
    Inventors: Roger NITSCH, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Publication number: 20150147805
    Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Jill Carton, Jin Lu, Bernard Scallon, Linda Snyder
  • Patent number: 9040295
    Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: May 26, 2015
    Assignee: Gene Techno Science Co., Ltd.
    Inventors: Shigeyuki Kon, Toshimitsu Uede
  • Publication number: 20150140591
    Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 21, 2015
    Inventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
  • Publication number: 20150140607
    Abstract: The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a CHO cell line. More specifically, the invention pertains to a combination of (i) a DNA vector suitable for production of a recombinant protein, wherein said vector comprises a sequence coding for a glutamine synthetase, and (ii) a Chinese Hamster Ovary (CHO) cell line, wherein said GS comprises a sequence at least 94.5% identical to the sequence of SEQ ID NO: 1 or to the sequence of SEQ ID NO: 2.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Applicant: SANOFI
    Inventors: Catherine Devaud, Bruno Dumas, Nabil Lounis
  • Patent number: 9034643
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 19, 2015
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Publication number: 20150125449
    Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 7, 2015
    Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter Von Kreudenstein
  • Patent number: 9005963
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: April 14, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • Patent number: 9005974
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: April 14, 2015
    Assignees: Academish Medisch Centrum Bij de Universiteit van Amsterdam, AIMM Therapeutics B.V.
    Inventor: Hergen Spits
  • Publication number: 20150098956
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Patent number: 8999707
    Abstract: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: April 7, 2015
    Assignee: Thomas Jefferson University
    Inventors: Scott K. Dessain, Sharad P. Adekar
  • Publication number: 20150093790
    Abstract: The disclosure provides thermostable enzymes isolated from Caldicellulosiruptor bescii and fragments thereof useful for the degradation of cellulose and/or hemicellulose, including thermostable cellulases and hemicellulases. The disclosure further provides nucleic acids encoding the thermostable enzymes of the disclosure. The disclosure also provides methods for the conversion of cellulose and hemicellulose into fermentable sugars using thermostable enzymes of the disclosure. The disclosure also provides enzyme cocktails containing multiple enzymes disclosed herein. The enzymes can be used to release sugars present in cellulose or hemicellulose for subsequent fermentation to produce value-added products.
    Type: Application
    Filed: December 20, 2011
    Publication date: April 2, 2015
    Applicant: The Board pf Trustees of the University of Illinois
    Inventors: Yejun Han, Xiaoyun Su, Dylan Dodd, Roderick I. Mackie, Issac K.O. Cann
  • Patent number: 8986954
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • Patent number: 8986990
    Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 24, 2015
    Assignee: Case Western Reserve University
    Inventors: John R. Schreiber, Kulwant Kaur
  • Patent number: 8986972
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 24, 2015
    Assignee: Stem CentRx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Publication number: 20150079070
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: March 10, 2014
    Publication date: March 19, 2015
    Applicant: Genzyme Corporation
    Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
  • Publication number: 20150082471
    Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventors: Marie-Cecile van de Lavoir, Robert Etches
  • Patent number: 8980582
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: March 17, 2015
    Assignee: Eli Lilly and Company
    Inventors: Neungseon Steven Seo, Stephanie Marie Eaton Truhlar
  • Patent number: 8981072
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 17, 2015
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
  • Patent number: 8980257
    Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: March 17, 2015
    Assignee: Medical & Biological Laboratories Co., Ltd.
    Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
  • Patent number: 8975391
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 10, 2015
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Barbara Enenkel
  • Patent number: 8969539
    Abstract: This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3? terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: March 3, 2015
    Assignee: JN Biosciences LLC
    Inventors: Naoya Tsurushita, J. Yun Tso
  • Patent number: 8969531
    Abstract: The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francisco Leon
  • Patent number: 8969040
    Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: March 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
  • Patent number: 8962819
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Adienne S.A.
    Inventors: Francesco Tedesco, Roberto Marzari
  • Patent number: 8962315
    Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Elwha LLC
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel
  • Patent number: 8962290
    Abstract: A method of increasing animal cell growth and monoclonal antibody production in an animal cell or cell culture includes the use of ultrasound at a frequency greater than about 1 MHz.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: February 24, 2015
    Assignee: Intelligentnano Inc.
    Inventors: Jie Chen, James Xing, Woon T. Ang, Hilal Gul
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 8956832
    Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: February 17, 2015
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
  • Patent number: 8957193
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 17, 2015
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 8951790
    Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: February 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Deba P. Saha